BMS-986318 / BMS - LARVOL DELTA

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis. (PubMed, J Med Chem) - "Compound 32 demonstrated robust antifibrotic efficacy despite reduced activation of certain genes in the liver, suggesting that the additional pharmacology of BMS-986318 does not further benefit efficacy, possibly presenting an opportunity for reduced adverse effects. Further evaluation in humans is warranted to validate this hypothesis."

Journal • Addiction (Opioid and Alcohol) • Dermatology • Fibrosis • Hepatology • Non-alcoholic Steatohepatitis • Pruritus

Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis. (PubMed, ACS Med Chem Lett) - "Compound 1 exhibits potent in vitro and in vivo activation of FXR, has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis. The overall profile of compound 1 supports its continued evaluation."

Journal • Cholestasis • Fibrosis • Hepatology • Immunology • Non-alcoholic Steatohepatitis

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Bristol-Myers Squibb; N=48 ➔ 0; Trial completion date: Oct 2020 ➔ Sep 2019; Active, not recruiting ➔ Withdrawn; Trial primary completion date: May 2020 ➔ Sep 2019

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants (clinicaltrials.gov) - P1; N=48; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed